1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Shkreli's Indictment May Help Industry Escape His Shadow

 
• By Brenda Sandburg

Having a pharma CEO arrested usually wouldn't be good news for industry – except it’s this guy.

The arrest and indictment ofTuring Pharmaceuticals AG CEO Martin Shkreli may benefit the pharmaceutical industry in its efforts to distance itself from the political firestorm caused by his drug pricing strategy.

While the government’s allegations pertain to his handling of investor funds during his tenure as CEO of Retrophin Inc.,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions

 
• By Sarah Karlin-Smith

Pfizer still has not submitted a supplemental biologics license application for the youngest population even though people familiar say it has dominated that market. Moderna says it can “step up” supply.

Aurobindo Expects US FTC Will Allow Lannett Acquisition

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will meet US FTC standards after an attempt to acquire Sandoz assets was nixed in 2020. The deal also could widen Aurobindo’s US manufacturing presence.

Inside Elamipretide’s CRL: Clinical And Surrogate Evidence Deficiencies, And A Path Forward

 
• By Sue Sutter

The Pink Sheet takes an exclusive look at the complete response letter, which shows the information on application deficiencies that could become widely available if FDA leaders succeed in releasing CRLs in real time.